{"name":"Accuray Incorporated","slug":"accuray","ticker":"ARAY","exchange":"NASDAQ","domain":"accuray.com","description":"Accuray is a radiation therapy company that develops, manufactures, and sells radiation therapy systems to deliver treatments including stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). It is the developer of innovative technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, the latest generation TomoTherapy platform. The company is headquartered in Sunnyvale, CA, the United States. The platforms are installed in leading healthcare centres in approximately 50 countries globally.","hq":"Sunnyvale, CA","founded":0,"employees":"990","ceo":"Suzanne Winter","sector":"MedTech / Radiation Oncology","stockPrice":0.29,"stockChange":-0.01,"stockChangePercent":-3.33,"marketCap":"$34M","metrics":{"revenue":428571008,"revenueGrowth":-7.4,"grossMargin":26.9,"rdSpend":47942000,"netIncome":-1591000,"cash":57416000,"dividendYield":0,"peRatio":-1.2,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Accuray Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Accuray reported revenue of $74.4 million for the fourth quarter of 2023, a decrease of 10% compared to the same period in 2022. The company also reported a net loss of $13.2 million for the quarter.","drugName":"","sentiment":"neutral"},{"date":"2023-09-14","type":"deal","headline":"Accuray Announces Agreement with Varian Medical Systems","summary":"Accuray announced an agreement with Varian Medical Systems to collaborate on the development of new radiation oncology products.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-02-17","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPVFBUYmQ4N3lHZmJWTHEtYVRyTUQwTHkwZFhoOU1zM1lnalBaaGx1TmRuQk5wdkdxVDlHM2NjUDRWVWxRTzcxenA3U3hiamMtNlNHa0puVWNtNkY5TXQ1b3J2REthSllKdXFaeXZPeW9tY3dITm5xNXJYeWRORnVOSkhrcU5GRjMtajlHN1RIdWtySWxxamgzc29iLWNQejF1X1M4ZVhUMA?oc=5","date":"2026-02-06","type":"pipeline","source":"Seeking Alpha","summary":"Groundhog Day Once Again, As Accuray Misses And Lowers - Seeking Alpha","headline":"Groundhog Day Once Again, As Accuray Misses And Lowers","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQZV9YaklJUHJIT0N1Y1h5QXludTVYdzZGM1NzTmYyd3ZyMThGa2JhZzBGNVFfRGhPdnR5NjdUXzFVeUZLNDROaDhIWWZBc3JMMEdVR0VjT1JrZHJodW9ka1A0M0l4TlF0S0R0dUhpUkFtUTllQ0k0eHhBU2JkUzlkcS05WS1HT2Q4UlBENWVGMlRyX0w2dzROLXI4bDRXZmhKTWx3YUViUjN1ZE8zTkpPZXNndGRydnM?oc=5","date":"2026-02-04","type":"earnings","source":"PR Newswire","summary":"Accuray Reports Fiscal 2026 Second Quarter Financial Results - PR Newswire","headline":"Accuray Reports Fiscal 2026 Second Quarter Financial Results","sentiment":"neutral"},{"date":"2026-02-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-15","type":"trial","source":"PR Newswire","summary":"Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company expects first phase to improve annualized operating profitability by approximatel","headline":"Accuray announces first phase of comprehensive strategic, operational, and organizational transformation plan; company e","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPSGotOHJBTjkxQjlqRFctekNaN0lSTGlqWWhCRFBSWi1NWHlGcWlLWDVOWF94ZUtGMVdsTWxZMzJSeG9RZW96NzZtdElVWTltMW02YWFHMUF6OTFtbkdoSm9KZFdSMzc4aVR0TUNJdGVuOWwzLS1CaVR5Qmw4VFJZbGZ0NC1vQXM2LU5VbkFQNWJiOWVQdldydXpvNVYxWnkzeUZFM25QWUp2S3c1?oc=5","date":"2025-11-06","type":"pipeline","source":"Seeking Alpha","summary":"Accuray’s Latest Transformation Attempt Could Be Too Little Too Late (NASDAQ:ARAY) - Seeking Alpha","headline":"Accuray’s Latest Transformation Attempt Could Be Too Little Too Late (NASDAQ:ARAY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOeU1DMXVlbUEwQTAwNUplNnZyVlJFUUxMeXpRajFYb3pORzZnMmdaNnhkV3A1d2FseVhPUlZQY0xYYzEwTE5HUHFTSHNDRlpFUmZYUDhJV1o5WEdfcDdsdDlNeGthbV9IZ2lhOXBjN1FwTFVlOFh5Zk1JR1ROQ1g2RTkzLWozVmN1djRtcDdSWk9tdDYwSzl0NGtnZzk0RDdFWDRDaW4tQUc1WE9PYWg1OU9RNTBsUQ?oc=5","date":"2025-11-05","type":"earnings","source":"PR Newswire","summary":"Accuray Reports Fiscal 2026 First Quarter Financial Results - PR Newswire","headline":"Accuray Reports Fiscal 2026 First Quarter Financial Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxPQkg4UnlrMUJoX2tFVzJSX0xfS1lpQkUyaF9BRUt1Ty1pcE5KdWxubWRIVnNjLW9KZFc4NHphNnp3c1NONWRnYXF4NWNaOTRMbl96Vk5VMlJ4SHlia1VGV1R2NE1QSVJtVWw5dFI1Ry1rODRURWZKQ010U1ozLXA3a1pBa1JiRFF0M1VTako1QXBwdk1MdHdaTG96RWRhcXZKa2xUSVFQVjhfamtObnhLQ1k5OGJIbFFLQzlF?oc=5","date":"2025-10-28","type":"earnings","source":"Stock Titan","summary":"Accuray (NASDAQ: ARAY) to report Q1 FY2026 results on Nov 5, webcast available - Stock Titan","headline":"Accuray (NASDAQ: ARAY) to report Q1 FY2026 results on Nov 5, webcast available","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNXzFDbmVNSDZGZ0NzamhMN0hjd0xxbHVybnRsbWRtOXhCaVlSbDFRcXVvWU9PeVJPWExaTHo4WlBJSEtHS29lSmdueGdaWDBCRWM1enphZ241Rm1LN1dvWXhxZmtEaVhBR3JBZVJzTXRIWTYyNUdMVHhjcTVuN2ZPX1p2aU5PdEttSXJuTThZcWFwajkza01CVmhMTnV3Y0EwQmxIUVlQYWpxWFJ5MktFVlFvYW51U0NKYi1xWTlUOWZacGwyM1NueW9hUThqWGViNC1sMlJSM1YyNFlIUFpJaDN3eEoxcW0xckRSVllGZ1p4UmZmTkhRcFhQS3N2bEdwSU9fVURRU2lablcyeGc?oc=5","date":"2025-10-08","type":"pipeline","source":"PR Newswire","summary":"Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife® System - PR Newswire","headline":"Accuray Announces Milestone for Cancer Patients in Melbourne, Australia with First SBRT Treatments Using the CyberKnife®","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Varian Medical Systems","Elekta","Isoray Medical"],"therapeuticFocus":["Radiation Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":113786000,"revenuePeriod":"2018-06-30","revenueHistory":[{"value":113786000,"period":"2018-06-30"},{"value":99832000,"period":"2018-03-31"},{"value":100329000,"period":"2017-12-31"},{"value":90950000,"period":"2017-09-30"},{"value":112094000,"period":"2017-06-30"},{"value":97312000,"period":"2017-03-31"}],"grossProfit":146967000,"grossProfitHistory":[{"period":"2025-06-30","value":146967000},{"period":"2024-06-30","value":142921000},{"period":"2023-06-30","value":153960000},{"period":"2022-06-30","value":159955000}],"rdSpend":47942000,"rdSpendHistory":[{"period":"2025-06-30","value":47942000},{"period":"2024-06-30","value":49732000},{"period":"2023-06-30","value":57129000},{"period":"2022-06-30","value":57752000}],"sgaSpend":91186000,"operatingIncome":7839000,"operatingIncomeHistory":[{"period":"2025-06-30","value":7839000},{"period":"2024-06-30","value":504000},{"period":"2023-06-30","value":2382000},{"period":"2022-06-30","value":8148000}],"netIncome":-1591000,"netIncomeHistory":[{"period":"2025-06-30","value":-1591000},{"period":"2024-06-30","value":-15545000},{"period":"2023-06-30","value":-9280000},{"period":"2022-06-30","value":-5347000}],"eps":-0.02,"epsHistory":[{"period":"2025-06-30","value":-0.02},{"period":"2024-06-30","value":-0.16},{"period":"2023-06-30","value":-0.1},{"period":"2022-06-30","value":-0.06}],"cash":57416000,"cashHistory":[{"period":"2025-06-30","value":57416000},{"period":"2024-06-30","value":68570000},{"period":"2023-06-30","value":89402000},{"period":"2022-06-30","value":88737000}],"totalAssets":470239000,"totalLiabilities":389070000,"totalDebt":176377000,"equity":81169000,"operatingCashflow":2860000,"operatingCashflowHistory":[{"period":"2025-06-30","value":2860000},{"period":"2024-06-30","value":-11904000},{"period":"2023-06-30","value":15539000},{"period":"2022-06-30","value":-2400000}],"capex":-8523000,"capexHistory":[{"period":"2025-06-30","value":-8523000},{"period":"2024-06-30","value":-3601000},{"period":"2023-06-30","value":-12681000},{"period":"2022-06-30","value":-4717000}],"freeCashflow":-5663000,"dividendsPaid":null,"buybacks":0,"employees":990,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":19664000,"ebit":-2891000,"ebitda":-813000,"period":"2026-03-31","revenue":104845000,"epsBasic":-0.09,"netIncome":-11805000,"rdExpense":8178000,"epsDiluted":-0.09,"grossProfit":25294000,"operatingIncome":-2548000},{"sga":18913000,"ebit":-5488000,"ebitda":-3325000,"period":"2025-12-31","revenue":102241000,"epsBasic":-0.11,"netIncome":-13770000,"rdExpense":10650000,"epsDiluted":-0.11,"grossProfit":24072000,"operatingIncome":-5491000},{"sga":26492000,"ebit":-13155000,"ebitda":-11479000,"period":"2025-09-30","revenue":93942000,"epsBasic":-0.18,"netIncome":-21678000,"rdExpense":11369000,"epsDiluted":-0.18,"grossProfit":26548000,"operatingIncome":-11313000},{"sga":23275000,"ebit":6297000,"ebitda":7895000,"period":"2025-06-30","revenue":127543000,"epsBasic":0.01,"netIncome":1123000,"rdExpense":11470000,"epsDiluted":0.01,"grossProfit":38979000,"operatingIncome":4234000},{"sga":19868000,"ebit":2050000,"ebitda":3625000,"period":"2025-03-31","revenue":113243000,"epsBasic":-0.01,"netIncome":-1297000,"rdExpense":10712000,"epsDiluted":-0.01,"grossProfit":31627000,"operatingIncome":1047000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.29,"previousClose":0.3,"fiftyTwoWeekHigh":2.1,"fiftyTwoWeekLow":0.28,"fiftyTwoWeekRange":"0.28 - 2.1","fiftyDayAverage":0.42,"twoHundredDayAverage":0.99,"beta":1.43,"enterpriseValue":180257040,"forwardPE":-1.2,"priceToBook":0.81,"priceToSales":0.08,"enterpriseToRevenue":0.42,"enterpriseToEbitda":-32.23,"pegRatio":0,"ebitda":-5592000,"ebitdaMargin":-1.3,"freeCashflow":-10882000,"operatingCashflow":-19116000,"totalDebt":182396992,"debtToEquity":437.3,"currentRatio":1.42,"returnOnAssets":-1.7,"returnOnEquity":-101.1,"analystRating":"3.0 - Hold","recommendationKey":"hold","numberOfAnalysts":1,"targetMeanPrice":0.35,"targetHighPrice":0.35,"targetLowPrice":0.35,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":4.1,"institutionHeldPercent":69.5,"sharesOutstanding":118963696,"floatShares":113055959,"sharesShort":6890759,"shortRatio":5.41,"shortPercentOfFloat":5.8,"epsTrailing":-0.38,"epsForward":-0.24,"revenuePerShare":3.64,"bookValue":0.35,"officers":[{"age":45,"name":"Mr. Ali  Pervaiz","title":"Senior VP & CFO"},{"age":66,"name":"Mr. Stephen R. LaNeve MBA","title":"President, CEO & Director"},{"age":46,"name":"Mr. Michael J. Murphy CPA","title":"Corporate Controller & Principal Accounting Officer"},{"age":null,"name":"Mr. John M. Dunn","title":"Senior VP, Chief Information Officer"},{"age":null,"name":"Mr. David  Shin","title":"Senior VP, Chief Legal Officer & Corporate Secretary"},{"age":null,"name":"Beth  Kaplan","title":"Public Relations Director"},{"age":null,"name":"Dr. Seth  Blacksburg M.B.A., M.D.","title":"Senior VP and Chief Medical & Marketing Officer"},{"age":null,"name":"Ms. Melanie  Rivers","title":"Senior VP, Chief Human Resources Officer"}],"industry":"Medical Devices","irWebsite":"http://investors.accuray.com/phoenix.zhtml?c=177244&p=irol-irhome","website":"https://www.accuray.com","phone":"608 824 2800"}}